Mechanisms of heart failure: Emerging molecular targets

Drug Discovery Today: Disease Mechanisms

Volumn 1, Issue 1, 2004, Pages 9-15

  Wehrens, Xander H T ^a   Marks, Andrew R ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 [4 (4 NITROBENZYLOXY)PHENYL]ETHYL]ISOTHIOUREA METHANESULFONATE; 2 [4 (2,5 DIFLUOROBENZYLOXY)PHENOXY] 5 ETHOXYANILINE; 4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NOLOMIROLE; PROTEIN CALSTABIN2; PROTEIN INHIBITOR; PROTEIN SUBUNIT; RYANODINE RECEPTOR; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CLINICAL TRIAL; DISEASE CLASSIFICATION; ENZYME MECHANISM; ENZYME RELEASE; HEART ARRHYTHMIA; HEART CONTRACTION; HEART FAILURE; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 23744456558     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2004.06.001     Document Type: Review

References (25)

1. Hunt, S.A. et al. (2001) ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J. Am. Coll. Cardiol. 38, 2101-2113
2. Cohn, J.N. et al. (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 311 (13), 819-823
3. 2+ content in isolated failing and nonfailing human myocardium. Circ. Res. 85 (1), 38-46
4. Marx, S.O. et al. (2000) PKA phosphorylation dissociates fkbp12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101, 365-376
5. McKenzie, D.B. and Cowley, A.J. (2003) Drug therapy in chronic heart failure. Postgrad. Med. 79, 634-642
6. Wehrens, X.H. and Marks, A.R. (2003) Altered function and regulation of cardiac ryanodine receptors in cardiac disease. Trends Biochem. Sci. 28 (12), 671-678
7. Hajjar, R.J. et al. (1998) Modulation of ventricular function through gene transfer in vivo. Proc. Natl. Acad. Sci. U.S.A. 95 (9), 5251-5256
8. del Monte, F. et al. (2002) Targeting phospholamban by gene transfer in human heart failure. Circulation 105 (8), 904-907
9. Haghighi, K. et al. (2003) Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J. Clin. Invest. 111 (6), 869-876
10. 2+ exchanger inhibitors SEA0400 and KB-R7943. Am. J. Physiol. Heart Circ. Physiol. 284 (3), H903-H910
11. Marx, S.O. et al. (2001) Phosphorylation-dependent Regulation of Ryanodine Receptors. A novel role for leucine/isoleucine zippers. J Cell Biol. 153 (4), 699-708
12. Wehrens, X.H. et al. (2003) FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 113 (7), 829-840
13. Marx, S.O. et al. (2001) Coupled gating between cardiac calcium release channels (ryanodine receptors). Circ. Res. 88 (11), 1151-1158
14. Fill, M. and Copello, J.A. (2002) Ryanodine receptor calcium release channels. Physiol Rev 82 (4), 893-922
15. 2+ release. Circ. Res. 92 (8), 904-911
16. Rockman, H.A. et al. (2002) Seven-transmembrane-spanning receptors and heart function. Nature 415 (6868), 206-212
17. Yano, M. et al. (2003) FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation 107, 477-484
18. MERIT-HF, (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (9169), 2001-2007
19. Reiken, S. et al. (2003) Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 107 (19), 2459-2466
20. Lowes, B.D. et al. (2002) Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N. Engl. J. Med. 346 (18), 1357-1365
21. Masson, S. et al. (2001) CHF-1024* a DA2/alpha2 agonist, blunts norepinephrine excretion and cardiac fibrosis in pressure overload. Cardiovasc. Drug Ther. 15, 131-138
22. CIBIS-II. (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (9146), 9-13.
23. Prestle, J. et al. (2001) Overexpression of FK506-binding protein FKBP12.6 in cardiomyocytes reduces ryanodine receptor-mediated Ca(2+) leak from the sarcoplasmic reticulum and increases contractility. Circ. Res. 88 (2), 188-194
24. Hoshijima, M. et al. (2002) Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat. Med. 8 (8), 864-871
25. Wahr, PA. et al. (1999) Parvalbumin gene transfer corrects diastolic dysfunction in diseased cardiac myocytes. Proc. Natl. Acad. Sci. U.S.A. 96, 11982-11985